Credit markets are overstating credit risk with a YTW of 6.853% relative to an Intrinsic YTW of 6.083% and an Intrinsic CDS of 139bps. Meanwhile, credit markets are materially overstating the firm's fundamental credit risk, with its Ba3 credit rating five notches lower than Valens' IG4+ (Baa1) credit rating. Incentives Dictate Behavior™ analysis highlights mixed signals for credit holders. As a positive, management members are material owners of PBF equity relative to their annual compensation,...
RxSight, Inc. Reports First Quarter 2024 Financial Results ALISO VIEJO, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today reported financial results for the three months ended March 31, 2024. Key Quarterly Highlights Reported first quarter 2024 revenue of $29.5 million, an increase of 69% compared to the first quarter of 2023, reflecting: The sale of 20,218 Light Adjustable Lenses (LAL®/LAL+™), representing a 92% ...
RCM Technologies, Inc. Announces Conference Call PENNSAUKEN, N.J., May 06, 2024 (GLOBE NEWSWIRE) -- RCM Technologies, Inc. (NasdaqGM: RCMT) will hold a conference call on Thursday, May 9, 2024 at 11:30 a.m. Eastern time to discuss the financial results for the thirteen weeks ended March 30, 2024. The teleconference dial-in numbers are (800) 285-6670 for domestic callers and (713) 936-6995 for international callers. About RCM RCM Technologies (NasdaqGM: RCMT) is a business and technology solutions provider with world-class talent in key market segments. We help design, build, and enable ...
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SOUTH SAN FRANCISCO, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on April 30, 2024 it granted stock options to purchase an aggregate of 29,646 shares of common stock and 17,012 shares of restricted stock units (RSUs) convertible into shares of common stock upon vesting to five new employees, whose employment commenced in April 2024, as a material inducement to their employment. The RSUs will vest over 3 years, with 40% of the RSUs vesting on the first ...
Recursion to Report First Quarter 2024 Business Updates and Financial Results on May 9 Company to host public L(earnings) Call on May 9 at 5:00 pm ET SALT LAKE CITY, May 02, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, announced today it will provide business updates and report its first quarter 2024 financial results on Thursday, May 9, 2024, following the close of the financial markets. Additionally, Recursion will host its quarterly L(earnings) Call on May 9, 2024 at 5:00 pm Eastern Time / 3:00 ...
Remitly Reports First Quarter 2024 Results Active customers up 36% year over yearSend volume up 34% year over yearRevenue up 32% year over year SEATTLE, May 01, 2024 (GLOBE NEWSWIRE) -- Remitly Global, Inc. (NASDAQ: RELY), a trusted provider of digital financial services that transcend borders, reported results for the first quarter ended March 31, 2024. “We are pleased with our strong start to the year that reflects our resilient customer base and superior customer experience,” said Matt Oppenheimer, co-founder and Chief Executive Officer, Remitly. “Our global scale and co...
RxSight, Inc. to Present at the Bank of America Healthcare Conference ALISO VIEJO, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced plans to participate in the upcoming Bank of America Healthcare Conference. RxSight’s management is scheduled to present on Wednesday, May 15, 2024, at 10:00 a.m. Pacific Time / 1:00 p.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation at: . About RxSight, Inc. ...
Recursion to Participate in Upcoming Investor Conferences SALT LAKE CITY, May 01, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced its participation in the following investor conferences: Bank of America Securities Healthcare Conference – May 14-16, 202452nd Annual JP Morgan Global Technology Conference – May 20-22, 2024 About Recursion is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recur...
Altitude Lab Secures Small Business Administration Growth Fund Accelerator Grant to Launch Horizon, a Commercialization Partnering Program The grant designates Altitude Lab as a top acceleration program for biotechnology startups SALT LAKE CITY, April 30, 2024 (GLOBE NEWSWIRE) -- Altitude Lab and the Small Business Administration (SBA) are pleased to announce Horizon, a commercialization program to connect startups to distributors, biopharma partners, and strategic investors in major biotech hubs nationwide, providing education on deal structures while driving awareness of Altitude Lab'...
CVR Energy Reports First Quarter 2024 Results and Announces a Cash Dividend of 50 Cents SUGAR LAND, Texas, April 29, 2024 (GLOBE NEWSWIRE) -- CVR Energy, Inc. (“CVR Energy” or the “Company”) (NYSE: CVI) today announced net income attributable to CVR Energy stockholders of $82 million, or $0.81 per diluted share, on net sales of $1.9 billion for the first quarter of 2024, compared to net income attributable to CVR Energy stockholders of $195 million, or $1.94 per diluted share, on net sales of $2.3 billion for the first quarter of 2023. Adjusted earnings for the first quarter of 2024 was 4...
Cytokinetics to Host Investor Event and Conference Call to Discuss the Primary Results From SEQUOIA-HCM at the European Society of Cardiology Heart Failure 2024 Congress SOUTH SAN FRANCISCO, Calif., April 29, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced it will host an investor event and conference call on May 13, 2024 at 4:00 PM Western European Summer Time (11:00 AM Eastern Time) to discuss the primary results from SEQUOIA-HCM (Safety, Efficacy, and Quantitative Understanding of Obstruction Impact of Aficamten in HCM), which are being presented in a...
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
Y-mAbs to Announce First Quarter 2024 Financial and Operating Results on May 7, 2024 The Company will host a conference call and webcast on Wednesday, May 8, 2024 at 8:00 a.m. ET NEW YORK, April 26, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that it will report its financial results for the quarter ended March 31, 2024, on Tuesday, May 7, 2024, after the close of the U.S. financial markets. The announcement will be followed by a conference call and webcast with the investment community on Wednesday, May 8, 2024, at 8:00 ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.